Lava Therapeutics
Lava Therapeutics is a developer of a bispecific antibody platform used to engage gamma-delta T cells for the treatment of cancer.
Lava Therapeutics has raised €70M across 1 funding round from 2 investors, most recently a Series C round in Sep 2020. Based in Utrecht, Netherlands; founded 2016; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€70M
€69,930,070
Funding rounds
1
Investors
2
distinct backers
Active since
2020-09
latest 2020-09
Funding by year
EUR raised per yearLava Therapeutics — funding by year — interactive chart.
Data table
| Lava Therapeutics — funding by year | |
|---|---|
| 2020 | €70M |
Signals
High confidenceRaise-next likelihood9
base rate 50% for Series C
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-09-17 | Series C | €70M | Novo Holdings,Sanofi Ventures | View deal → |
Investors
2Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Picnic€1.7BNetherlands · E-commerce
- Just Eat Takeaway€1.6BNetherlands · Foodtech
- Nebius€1.5BNetherlands · Cloud
- CMR Surgical€1.5BUK · Healthtech
Global coverage: FundingData